Zhejiang Medicine Co Ltd (600216) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin.
Total Revenue Chart for Zhejiang Medicine Co Ltd
Zhejiang Medicine Co Ltd (600216) revenue for FY2025 was CNY 8.9B, a -5.3% change from FY2024. Zhejiang Medicine Co Ltd's revenue grew from CNY 763.6M in 1996 to CNY 8.9B in 2025 (1063.0% over 29 years). Earnings per share grew from CNY 0.03 in 2000 to CNY 1.09 in 2021 (4134.9%). Revenue compound annual growth rate: 5-year CAGR of 3.9%, 10-year CAGR of 7.0%, 20-year CAGR of 8.1%.
Total Revenue (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥10.22B
- Implied Share Price
- ¥10.63
- Enterprise Value
- ¥7.37B
- Revenue (TTM)
- ¥8.43B
- EBITDA
- ¥1.32B
- Profit Margin
- 7.51%
- Trailing P/E
- 16.11
- Forward P/E
- 13.39
- Price/Book (MRQ)
- 0.89
- Price/Sales (TTM)
- 1.21
- EV/EBITDA
- 12.39
- EV/Revenue
- 0.87
- Dividend Yield
- 2.64%
- Book Value
- ¥11.84
- Free Cash Flow (FY2025)
- ¥1.44B
- Free Cash Flow Yield
- 14.08%
Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.